Invetech has introduced Korus, a new closed system for autologous cell therapies, to transform the industry standards in elutriation and cell wash.
The technology uses a mild elutriation process to supply a cleaner cell population for cell therapy production processes, such as tumour-infiltrated lymphocytes (TIL), dendritic cell, chimeric antigen receptor (CAR)-T cell or induced pluripotent stem cell (IPSC)-derived therapy.
It features elutriation and cell wash using gentle counterflow centrifugation.
Korus provides purified cell populations for downstream processing development as well as commercial manufacture.
This will help improve the overall performance of processes through higher recovery and purity of target cells.
Using the new Korus system, developers can expedite the clinical development and scale-out of their products.
According to the company, the system has the capability to transform cell therapy industry standards.
Invetech president Andreas Knaack said: “To fast-track the commercialisation of cell and gene therapies, our industry needs efficient and scalable manufacturing technologies that can deliver high-quality therapies cost-effectively.
“Invetech’s new technology offering, as demonstrated by our new Korus system, represents our continued commitment to helping make life-saving therapies accessible to more patients.”
When Korus technology is integrated into a cell therapy manufacturing process, better downstream performance, such as higher target cell recovery during selection processes and cell growth during expansion, can be obtained.
The company stated that the new system can result in a 49% improvement in T cell recovery after selection, 31% purer lymphocyte population, and 70% more T cells during expansion, compared to standard washing protocols.
Invetech cell therapy science and application team leader Jon Ellis said: “Our data shows that whilst achieving similar apheresis lymphocyte cell recovery to the control wash process, Korus eluted lymphocytes to high purity which resulted in improvements in downstream performance including greater Dynabead cell selection recovery and fold expansion.”
“Overall, this innovation in cell processing will reduce the impact of starting material variability, contribute to higher manufacturing yield and reduced risk of batch failure; and potentially reduce the cost of goods for future therapies.”